Cutler Group LP Exelixis, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	BUY	$14.96 - $17.39 $44,880 - $52,170	3,000 New	3,000 $0
Q4 2020 Jan 21, 2021	SELL	$18.39 - $24.8 $91,950 - $124,000	-5,000 Closed	0 $0
Q3 2020 Oct 27, 2020	BUY	$20.67 - $26.94 $76,479 - $99,678	3,700 Added 284.62%	5,000 $8,000
Q4 2019 Feb 06, 2020	SELL	$15.15 - $18.89 $75,750 - $94,450	-5,000 Reduced 79.37%	1,300 $0
Q2 2019 Aug 09, 2019	BUY	$18.93 - $24.75 $75,720 - $99,000	4,000 Added 173.91%	6,300 $12,000
Q1 2019 May 10, 2019	SELL	$19.6 - $24.76 $133,280 - $168,368	-6,800 Reduced 74.73%	2,300 $0
Q3 2018 Nov 07, 2018	BUY	$15.87 - $22.4 $142,830 - $201,600	9,000 Added 9000.0%	9,100 $9,000
Q2 2018 Aug 10, 2018	SELL	$18.56 - $22.45 $103,936 - $125,720	-5,600 Reduced 98.25%	100 $0
Q1 2018 May 11, 2018	SELL	$22.15 - $31.89 $183,845 - $264,687	-8,300 Reduced 59.29%	5,700 $0
Q4 2017 Jan 17, 2018	BUY	$24.23 - $30.93 $147,803 - $188,673	6,100 Added 77.22%	14,000 $56,000
Q3 2017 Oct 17, 2017	BUY	$23.35 - $29.24 $184,465 - $230,996	7,900	7,900 $22,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.